EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Model‐Informed Decision Making from Drug Discovery to Reimbursement: A Roadmap for Clinical Pharmacology in Value‐Based Healthcare

Rajesh Krishna iD, Ananth Kadambi, Patrick Smith, Piet H van der Graaf, Fran Brown iD

The Journal of Clinical Pharmacology · 2026

DOI: 10.1002/jcph.70270 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Rajesh Krishna und 4 weiteren Autor:innen. Beteiligte Einrichtung: Certara Drug Development Solutions, Certara USA, Inc., Radnor, PA, USA. Hauptthemen laut MEDLINE: Drug Discovery, Pharmacology, Clinical, Decision Making. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The transition to value‐based healthcare demands more efficient, evidence‐driven approaches to drug discovery, development and medical use. Clinical pharmacology is uniquely positioned to support this shift through model‐informed drug development (MIDD) decision‐making, integrating quantitative methods across the product lifecycle. This commentary outlines a roadmap for embedding MIDD from early drug discovery through regulatory evaluation and ultimately into reimbursement and real‐world use. We highlight how pharmacokinetic/pharmacodynamic modeling, mechanistic modeling, disease progression models, patient‐relevant endpoints, and real‐world data will inform dose selection, optimize trial design, and reduce uncertainty in benefit–risk and cost‐effectiveness assessments. Emphasis is placed on cross‐stakeholder alignment, including regulators, payers, clinicians, and industry, to ensure that model‐informed evidence translates into demonstrable patient and economic value. Key challenges, such as data integration, model transparency, and acceptance by decision‐makers, are discussed alongside practical solutions. By advancing a lifecycle‐based, quantitatively informed framework, clinical pharmacology can play a central role in delivering therapies that are not only safe and effective but also aligned with the principles of value‐based healthcare.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DiscoveryPharmacology, ClinicalDecision MakingHumansValue-Based Health CareCost-Benefit AnalysisDrug DevelopmentModels, Biological

Stichwörter der Autor:innen

clinical pharmacologymodel‐informed drug developmentpayer valuetotality of evidence

Autor:innen und Institutionen

  • Certara Drug Development Solutions, Certara USA, Inc., Radnor, PA, USA.
  • Certara Predictive Technologies, Certara, Sheffield, UK.

ORCID-Profile: Rajesh Krishna, Fran Brown

Zitieren

APA

Krishna, R., Kadambi, A., Smith, P., van der Graaf, P. H., & Brown, F. (2026). Model‐Informed Decision Making from Drug Discovery to Reimbursement: A Roadmap for Clinical Pharmacology in Value‐Based Healthcare. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70270

Vancouver

Krishna R, Kadambi A, Smith P, van der Graaf PH, Brown F. Model‐Informed Decision Making from Drug Discovery to Reimbursement: A Roadmap for Clinical Pharmacology in Value‐Based Healthcare. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70270

BibTeX
@article{Krishna2026,
  author = {Krishna, Rajesh and Kadambi, Ananth and Smith, Patrick and van der Graaf, Piet H and Brown, Fran},
  title = {Model‐Informed Decision Making from Drug Discovery to Reimbursement: A Roadmap for Clinical Pharmacology in Value‐Based Healthcare},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/jcph.70270}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche